50 completed, 26 terminated, 11 unknown, 3 withdrawn. 30 Phase 4, 20 Phase 2, 18 Phase 3, 9 Phase 1, 8 Not applicable.
Follow Daptomycin: new trials by email Literature Review of Daptomycin trials Research Report on Daptomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA - Staphylococcus Aureus Bacteremia | Phase 4 | Enrolling by invitation | West Virginia University | 300 | 2025-09-15 | 2026-09-17 |
| Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2024-11-14 | 2026-09-09 |
| Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial Cefazolin with Daptomycin, Cefazolin with vancomycin - Periprosthetic Joint Infection | Not applicable | Unknown | Chang Gung Memorial Hospital | 184 | 2024-08-01 | 2024-01-05 |
| Comparing Oral Versus Parenteral Antimicrobial Therapy Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection | Phase 4 | Terminated | West Virginia University | 94 | 2023-08-04 | 2025-08-26 |
| Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline - Endocarditis | Phase 4 | Terminated | West Virginia University | 5 | 2022-03-16 | 2026-05-05 |
| Staphylococcus Aureus Network Adaptive Platform Trial Cefazolin, Penicillin, Clindamycin - Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | University of Melbourne | 8000 | 2022-02-16 | 2026-05-06 |
| PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2021-09-14 | 2026-04-06 |
| Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections patients having had BJI or PJI treated with daptomycin - Dactinomycin Adverse Reaction, Bone and Joint Infection | Unknown | Hospices Civils de Lyon | 1130 | 2021-06-15 | 2022-05-06 | |
| DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia Cefazolin, Dalbavancin, Daptomycin - Staphylococcal Bacteraemia | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2021-04-22 | 2024-12-10 |
| Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®) Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®), Antibiotics - Hemodiafiltration, Sepsis | Completed | Hospital Universitari de Bellvitge | 20 | 2021-01-01 | 2023-10-10 | |
| A Pharmacokinetics Study of Daptomycin in Critically Ill Patients and Effects of Daptomycin on Kidney Daptomycin - Outcome, Fatal, Infection | Unknown | Zhongnan Hospital | 120 | 2020-12-01 | 2020-11-13 | |
| Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC) Daptomycin - Antibiotics, Subcutaneous Injection | Phase 1 | Completed | University Hospital, Caen | 12 | 2020-10-15 | 2026-04-14 |
| The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection. Daptomycin - Antibiotic | Unknown | Jiangsu Hengrui Pharmaceutical Co., Ltd. | 2000 | 2020-08-25 | 2020-09-17 | |
| Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI Xydalba, vancomycin, teicoplanin or daptomycin - Acute Bacterial Skin and Skin Structure Infection | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 184 | 2020-06-18 | 2022-03-04 | |
| Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) Piperacillin/tazobactam, Meropenem, Daptomycin - Therapeutic Drug Monitoring, Subarachnoid Hemorrhage | Unknown | Azienda Sanitaria-Universitaria Integrata di Udine | 104 | 2019-10-01 | 2021-07-21 | |
| Ceftriaxone as Home IV for Staph Infections Ceftriaxone, Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin) - Staphylococcal Infections, Osteomyelitis | Phase 4 | Unknown | Vancouver Island Health Authority | 310 | 2019-07-11 | 2019-10-28 |
| Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) Daptomycin for Injection - Bacteremia, Soft Tissue Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 18 | 2018-12-06 | 2022-05-13 |
| Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia Ceftobiprole medocaril, Daptomycin - Staphylococcus Aureus Bacteremia | Phase 3 | Completed | Basilea Pharmaceutica | 390 | 2018-08-26 | 2026-10-07 |
| Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis Daptomycin - Pneumococcal Meningitis | Phase 2 | Completed | Centre Hospitalier Universitaire Dijon | 112 | 2018-06-07 | 2024-10-01 |
| Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections Dalbavancin, Vancomycin - Bone Infection, Osteomyelitis | Phase 4 | Completed | Infectious Diseases Physicians, Inc. | 41 | 2018-01-25 | 2023-10-03 |
Showing 20 of 93. Sign in to see all of them.
Staphylococcal Infections (18) · Bacteremia (17) · Cellulitis (9) · Sepsis (8) · Endocarditis (7) · Gram-Positive Bacterial Infections (7) · Soft Tissue Infections (7) · Infections (6) · Osteomyelitis (5) · Abscess (3) · Acute Kidney Injury (3) · Arthritis, Infectious (3) · Bacterial Infections (3) · Diabetic Foot (3) · Endocarditis, Bacterial (3)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (22) · Duke University (3) · M.D. Anderson Cancer Center (3) · University of Zurich (3) · West Virginia University (3) · AstraZeneca (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · Andrej Trampuz (1) · Arrevus Inc. (1) · Azienda Sanitaria-Universitaria Integrata di Udine (1) · Aziende Chimiche Riunite Angelini Francesco S.p.A (1) · Basilea Pharmaceutica (1) · Cellceutix Corporation (1) · Centre Hospitalier Universitaire Dijon (1)
United States (46) · France (7) · Germany (7) · Italy (7) · Canada (6) · Spain (6) · China (5) · Switzerland (5) · Russia (4) · United Kingdom (3) · Australia (2) · Greece (2) · Israel (2) · Japan (2) · Netherlands (2)
Donald Poretz, MD (2) · Issam Raad, MD (2) · Paula Bokesch, MD (2) · Achim J Kaasch, MD (1) · Alistair Wheeler, MD (1) · Alistair Wheeler, MD, MFPM (1) · Andrej Trampuz (1) · Arif R Sawari, MD, MSc, MBA (1) · Arif R. Sarwari, MD, MSc, MBA (1) · Bruce A Mueller, PharmD (1) · Bruce Friedman, MD (1)
PMID 18444848, PMID 16914701, PMID 18316988, PMID 18662172, PMID 19222623, PMID 20462352, PMID 20890189, PMID 21176752, PMID 21317681, PMID 21444695, PMID 21649882, PMID 22908174, PMID 23085743, PMID 24943129, PMID 25361023, PMID 25762232, PMID 26072149, PMID 26452342, PMID 26547411, PMID 27682068, PMID 28202770, PMID 28288784, PMID 29406465, PMID 29859132, PMID 30264119, PMID 30858203, PMID 32051007, PMID 32639465, PMID 32725216, PMID 33767093, PMID 34920946, PMID 35578360, PMID 37491088, PMID 37754204, PMID 38244557, PMID 39271104, PMID 39456544, PMID 39934879, PMID 40802264, PMID 41419216, PMID 41433510, PMID 41999282, PMID 42308484, PMID 42309115
2009 (1), 2019 (1), 2025 (1), 5UM1AI104681-12 (1)